ecause vitamin D insufficiency can be harmful to health, 1-3 supplementation is often prescribed. However, the Food and Drug Administration (FDA) does not regulate vitamin D supplements, so potency may not be well evaluated. In a recent trial examining vitamin D in menopausal women, we found that compounded vitamin D 3 (cholecalciferol) supplements varied significantly in potency. Only one-third of our compounded study pills met US Pharmacopeial (USP) Convention standards, which require that compounded pills contain 90% to 110% of the active ingredient.
tion. To standardize variability and compare across doses, we calculated the coefficient of variation (CV)-the ratio of the standard deviation to the mean.
Results. Analysis of 5 Pills
From the Same Bottle. The OTC pillscontained52%to135%ofexpecteddose (Table) .When averaged over 5 pills, two-thirds of bottles met USP Convention standards for OTC cholecalciferol solution, 5 which statethatcontentsshouldbewithin90%to120%ofthestated dose. In approximately one-fourth of bottles, all 5 pills met USP Convention standards. Two-thirds of bottles had less than 10% variability (CV). The one manufacturer that was USP verified (No. 4) was highly accurate (101.7%), and all 5 pills tested were within 10% of expected dose.
Analysis of Pills From 5 Bottles With
The Same Lot Number. When we took 1 pill from each of 5 bottles with the same lot number, potency ranged from 57% to 138% of the stated amount (eTable 1). When pills in each lot were averaged, potencies ranged from 99.7% to 107%. Only the 5000 IU dose of the USP-verified manufacturer had pills from the same lot that all tested within 90% to 120% of the expected amount. The 1000 IU pills of that manufacturer were more variable (97% to 135% of the expected dose; CV, 13.0%). Variability of pills from the remaining manufacturers ranged from 7.1% to 27.9%; only 1 had less than 10% variability.
Analysis of Pills From 5 Bottles With Different Lot
Numbers. The potency of pills from different lots ranged from 9% to 140% of the stated dose; mean potencies over 5 lots ranged from 89% to 105% (eTable 2). Only the USPverified manufacturer had pills from different lots that were all within 90% to 120% of the expected dose (CV, 5.5%). The 1000-IU pills from the USP-verified manufacturer were more variable-potency ranged from 70% to 140% (CV, 23.3%). The pills from different lots of the remaining manufacturers were also variable (CVs, 11.3% to 58.2%).
Analysis of Compounded Pills. The compounded 50 000-IU cholecalciferol tablets contained 52% to 105% and the 1000 IU compounded tablets 23% to 146% of the expected dose. Only one-third of pills were within 10% of the expected dose, which is the USP Convention standard for compounded pills. 4 Variation in storage time did not explain potency differences.
Comment. The cholecalciferol content of OTC and compounded vitamins was highly variable; potency ranged from 9% to 146%. In our test, just over one-half of OTC pills and only one-third of compounded pills met USP Convention standards. The manufacturer that was USP verified (No. 4) was generally more accurate and less variable. Lack of accuracy in cholecalciferol dosing may not cause harm in most consumers. However, supplementation may be less effective and dose adjustments inaccurate in inconsistent users, 6 which may harm women with severe vitamin D deficiency. Pill variability may also threaten validity of vitamin D trials that use compounded pills to blind participants. As more people take vitamin D supplements, it is critical that health care providers and patients understand that cholecalciferol potency may vary widely. Products that are USP verified may have better accuracy but may be sparsely distributed. On the basis of our study, we agree with a recent editorial calling for increased regulation of dietary supplements.
